We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Toxins Help Anthrax Avoid Immune System

By Biotechdaily staff writers
Posted on 10 Sep 2002
In a recent study, researchers found a protein complex (lethal toxin, or LT) produced by Bacillus anthracis, the bacteria that causes anthrax, that is able to inhibit and destroy macrophages, the immune system's primary defense against such pathogens. More...
The study was published August 29, 2002, in the online journal Science Express.

Instead of being destroyed by the immune system, the anthrax bacteria survive and germinate within the macrophages and travel with them throughout the body to the lymph nodes, and eventually into the bloodstream, ultimately leading to fatal systemic shock if treatment fails.

The investigators, from the University of California, San Diego (UCSD, USA), looked for the mechanism used by the bacteria to evade destruction by the macrophages. They found that the bacteria manufacture a number of proteins that work together to disrupt macrophage function.

Another protein, called protective antigen (PA), binds to the cell surface and allows bacterial proteins to penetrate the macrophage. These proteins, termed lethal factor (LF), cleave and disable specific protein kinases (called mitogen activated protein kinase kinases, or MKKs) that play a vital role in activation of the p38 protein kinase, whose enzymatic activity is essential for survival of the macrophage. The authors of the current study believe that PA and LF function together in the form of LT, which inhibits p38. Inactivation of p38 leads to the death of the macrophage and prevents secretion of the chemokines and cytokines that would alert the immune system to the presence of an invading pathogen.

Dr. Michael Karin, professor of pharmacology at UCSD and the study's senior author, explained that anthrax and other deadly pathogens, such as bubonic plague, take several days or up to a week for symptoms to appear, as the body's normal immune response has been subdued. "We have wondered why this bug does not make patients sick early on, especially since it does not take many bacteria to make us sick. Feeling sick is actually good. It means we are fighting the effects of infection with a fever or runny nose. Not being sick means your immune system is not detecting the infection.”



Related Links:
U. of California, San Diego

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.